

Programme

12th European Health Forum Gastein

30th September to 3rd October 2009

Financial Crisis and Health Policy

Impact of the financial crisis on health

Health inequalities in Europe

Sustainable healthcare

Health Technology Assessment

Transferring good practice into action

International Forum Gastein
Tauernplatz 1, 5630 Bad Hofgastein, Austria

Tel: +43 (6432) 3393 270


Fax: +43 (6432) 3393 271

Email: info@ehfg.org


Web: www.ehfg.org



Programme overview



Programmüberblick



Günther Leiner
President European Health
Forum Gastein



In times of financial crisis and subsequent economic recession we want to draw attention to the impact on individual health as well as on health care. It's our intention to address challenges and opportunities for health systems, population health and the health of individuals. Developing appropriate policy responses to be considered at national and EU levels is our aim. In line with the call for leadership at the EHFG 2008, the global financial turmoil should not sway nations from existing commitments made to underpin health systems. Sustained and strengthened investment in health care and public health can make a valuable contribution to economic recovery as well as health. However, leadership and vision are required to grasp these opportunities.

In Zeiten der Finanzkrise und der darauf folgenden Rezession wollen wir den Schwerpunkt auf dessen Einfluss der individuellen Gesundheit und Versorgung legen. Es ist unsere Absicht Herausforderungen und Möglichkeiten für Gesundheitssysteme, der Gesundheit der Bevölkerung, sowie des Einzelnen, anzusprechen und darauf abzielen entsprechende Schritte in der Politik auf nationaler und EU Ebene zu setzen. Im Anschluss an den Aufruf zum mehr Leadership im Rahmen des EHFG 2008, sollten die globalen Finanzturbulenzen die Länder nicht von bestehenden Bekenntnissen zur Stärkung der Gesundheitssysteme abbringen. Nachhaltige und starke Investitionen in Versorgung und öffentliche Gesundheit kann einen wertvollen Beitrag zum wirtschaftlichen Aufschwung, sowie zur allgemeinen Gesundheit leisten. Wie auch immer, Leadership und Visionen sind auf diesem Gebiet erforderlich, um diese Chancen wahrnehmen zu können.

Plenary sessions

Financial crisis – Challenges and opportunities for health Finanzkrise – Herausforderungen und Möglichkeiten für Gesundheit

Wednesday, 30 September 2009
 12:30 – 14:30

Welcome and Opening Begrüßung und Eröffnung	<i>F Zettinig, Mayor, Bad Hofgastein</i> <i>E Scharer, Member of Provincial Government (health), Salzburg</i> <i>G Leiner, President, EHFG</i>
Introduction by Chief Rapporteur Einleitung durch den Chief Rapporteur	<i>T Rose, Independent EU Health Advocate, Brussels, Belgium</i>
Health impact of economic crisis Einfluss der Wirtschaftskrise auf die Gesundheit	<i>D Stuckler, Social Epidemiologist, Oxford University, UK</i>
Crisis and social determinants of health Krise und soziale Gesundheitsdeterminanten	<i>M Marmot, Director, International Institute for Society and Health</i>
Economic crisis: opportunities and commitments for health Wirtschaftskrise: Möglichkeiten für und Bekenntnis zur Gesundheit	<i>N Menabde, Deputy Regional Director, WHO Regional Office, Europe</i>

European Health Award Ceremony

This year for the third time the European Health Forum Award will be awarded to a European health policy initiative that has contributed in a clear and significant way to meeting a key challenge in public health or health services.

European Health Award Preisverleihung

Dieses Jahr wird der European Health Forum Award zum dritten Mal vergeben, um eine europäische gesundheitspolitische Initiative auszuzeichnen, die in signifikanter Weise eine Schlüsselherausforderung in der öffentlichen Gesundheit oder der Gesundheitsversorgung löst.



Opening of Joint DG Research & DG SANCO Poster Session Eröffnung der gemeinsamen Poster Session von GD Forschung & GD Gesundheit	<i>R Madelin, Director General, DG Health and Consumers, European Commission</i>
---	--

Financial crisis and health – A time for leadership Finanzkrise und Gesundheit – Zeit für Leadership

Friday, 2 October 2009 Chair: *M McKee, Head of Research Policy, European Observatory on Health Systems and Policies*
 13:00 – 15:30

Conference video report by Chief Rapporteur Kongresszusammenfassung des Chief Rapporteurs	<i>T Rose, Independent EU Health Advocate, Brussels, Belgium</i>
Keynote presentations	<i>A Vassiliou, EU Commissioner for Health</i> <i>A Stöger, Minister of Health, Austria</i>
Panel discussion	<i>L Hyssälä, Minister of Health and Social Services, Finland</i> <i>M Sacconi, Minister of Health, Italy (tbc)</i> <i>N Klusen, Chairman of the Board, Techniker Krankenkasse (statutory health insurance), Germany</i> <i>G Magnusson, Professor of Public Health, Reykjavik University, Iceland</i> <i>M Medgyaszai, Secretary of State for Health Policy, Hungary</i> <i>E Muschik, Vice-President, Mental Health Europe</i> <i>W Molterer, MP, former Vice-Chancellor and Finance Minister, Austria</i>
Closing presentations	<i>W Haslauer, Deputy Governor, Salzburg</i> <i>G Leiner, President, EHFG</i>

Simultaneous interpretation in English and German Simultanübersetzung in Englisch und Deutsch

Forum 1

Sustainability of health systems

Nachhaltigkeit von Gesundheitssystemen

Sustainability of health systems – the impact of the financial and economic crisis on health

The current financial and economic crisis is expected to have a major impact on the sustainability of health care systems and the health of the population. This forum aims to analyse the potential impact of the crisis, look at the challenges faced by society and seek potential solutions.

Nachhaltigkeit von Gesundheitssystemen – Der Einfluss der Finanz- und Wirtschaftskrise auf die Gesundheit

Die derzeitige Finanz- und Wirtschaftskrise wird vermutlich einen großen Einfluss auf die Nachhaltigkeit unserer Gesundheitssysteme und auf die Gesundheit der Bevölkerung haben. Dieses Parallelforum wird die möglichen Auswirkungen der Krise analysieren und nach Lösungen suchen.

Chair: K Walshe, Chair, EHMA Scientific Advisory Committee; Co-Chair: K Kuo, Director, National Health Research Institute, Taiwan

Rapporteur: E Nolte, Director, Health and Healthcare, Rand Europe

SESSION I	Setting the scene: Which countries, groups or businesses, the public or the private sector are most affected? Überblick: Welche Länder, Gruppen, Unternehmen – privater oder öffentliche Sektor – was ist am stärksten betroffen?	<i>A Fidler, Lead Adviser Health Policy, The World Bank</i>
Assessment of the impact of the current crisis		
Analyse des Einflusses der derzeitigen Krise	Medicine, money, morality and human rights Medizin, Moneten, Moral und Menschenrechte	<i>P Mierzewski, Head of Health Division, Council of Europe</i>
	Where are the safety nets for health finance in crisis? Experiences in Taiwan and Asia Wo sind die Sicherheitsnetze für die Finanzierung der Gesundheit in Zeiten der Krise? Erfahrungen aus Taiwan und Asien	<i>M Chen, Deputy Director, Bureau of National Health Insurance, Ministry of Health, Taiwan</i>
	How does the crisis influence the health care industry? Wie beeinflusst die Krise die Gesundheitswirtschaft?	<i>V Bronsema, Member National Associations Council, EuropaBio</i>

Moderated and facilitated by M McKee, Professor of European Public Health, London School of Hygiene & Tropical Medicine

Panel discussion: What is the impact of the crisis?
Podiumsdiskussion: Was sind die Auswirkungen der Krise?
G Fischer, Head of Unit, DG Employment and Social Affairs, European Commission
C Auer, Director General, Ministry of Health, Austria
L Bryndová, Chief Adviser to the Minister, Ministry of Health, Czech Republic (tbc)
J Figueras, Director, European Observatory on Health Systems and Policies
M Hofmarcher, Economist, Senior Researcher, Institute for Advanced Studies (IHS), Austria
LM Voipio-Pulkki, Member of the President's Committee, European Hospital and Healthcare Federation
M Kosinska, Secretary General, European Public Health Alliance

SESSION II	Public strategies for coping with economic downturn Öffentliche Strategien zur Bewältigung des wirtschaftlichen Abschwungs	<i>CC Yeh, Minister of Health, Taiwan</i>
Solutions to overcome the crisis: coping strategies and momentum for reform		
Lösungen für die Krise: Strategien für ihre Bewältigung und Momentum für Reformen	Health systems responses to the financial crisis Antworten der Gesundheitssysteme auf die Finanzkrise	<i>M McKee, Professor, London School of Hygiene & Tropical Medicine</i>
	What do patients expect? Was erwarten die Patienten?	<i>N Bedlington, Director, European Patients' Forum</i>
	Understanding the crisis – managing complexity – solutions to the crisis Krise verstehen – Komplexität managen – Lösungen für die Krise	<i>F Malik, President, Management Centre St. Gallen, Switzerland</i>

Moderated and facilitated by M McKee, Professor of European Public Health, London School of Hygiene & Tropical Medicine

Panel discussion: Who shall take the lead in overcoming the crisis?
Podiumsdiskussion: Wer soll die Führung zur Bewältigung der Krise übernehmen?
CC Yeh, Minister of Health, Taiwan
B Pettersson, Senior Adviser, Ministry of Health and Social Affairs, Sweden
J Bowis, MEP, European People's Party
A Rys, Director, DG Health and Consumers, European Commission
M Wilks, President, Standing Committee of European Doctors
N Klusen, Chairman of the Board, Techniker Krankenkasse (statutory health insurance), Germany

Hosted by the Ministry of Health, Taiwan

Simultaneous Interpretation in English and German

Simultanübersetzung in Englisch und Deutsch

Health Technology Assessment (HTA) – Burden or benefit in an economic crisis?

The increased pressure on health systems is a real challenge for HTA. Working together, sharing knowledge, creating values will be even more important in the future. Especially in times of economic crises with limited budgets HTA has become an indispensable instrument for any health system.

Gesundheitstechnologie-Bewertung (GTB) – Last oder Nutzen in der Wirtschaftskrise?

Der wachsende Druck auf Gesundheitssysteme ist eine echte Herausforderung für GTB. Zusammenarbeit, Wissenstransfer und die Schaffung von Werten werden in Zukunft immer wichtiger. Besonders in Zeiten ökonomischer Krisen mit begrenzten Finanzmitteln ist GTB für jedes Gesundheitssystem ein unverzichtbares Instrument.

Chair: P Kanavos, Senior Lecturer, London School of Economics, London

Rapporteur: M Rosenmöller, Senior Lecturer, University of Navarra, Barcelona

INTRODUCTION

The responsibilities of HTA in a modern society – can it meet the high expectations?

Die Verantwortung der GTB in der modernen Gesellschaft – Kann es die hohen Erwartungen erfüllen?

P Kanavos, Senior Lecturer, London School of Economics, London

SESSION I

Stakeholder involvement

Early, broad, active and continuous engagement of key stakeholders at all stages, operating in a partnership environment, will not only enable a full societal perspective but also improve acceptance and implementation.

FB Kristensen, Coordinating Secretariat and Chairman, EUnetHTA Executive Committee, National Board of Health, Denmark, Copenhagen

Stakeholdereinbindung

Das frühzeitige, aktive und andauernde Engagement der entscheidenden „Stakeholder“, die durchwegs in einer partnerschaftlichen Zusammenarbeit mitwirken, wird nicht nur die erforderliche volle gesellschaftliche Betrachtung ermöglichen sondern Akzeptanz und Umsetzung verbessern.

M Drummond, Professor, Centre for Health Economics, University of York, United Kingdom

SESSION II

Patient perspectives

There is a growing demand that all patients be enabled to choose between health care options and thus fully benefit from all innovations – medicines, devices, diagnostic tools and surgical procedures – independent of their costs.

M Ryan, Chair, Health Economics Research Unit, Aberdeen, United Kingdom

Patientenperspektive

Es gibt zunehmend Forderungen, allen Patienten zu ermöglichen zwischen Versorgungsoptionen auszuwählen, um ihnen volle Teilhabe an allen Innovationen wie neuen Arzneimitteln, diagnostischen Geräten und chirurgischen Verfahren, unabhängig von den Kosten zu gewährleisten.

C Bergdahl, Patient Representative, Swedish HTA Agency, Stockholm, Sweden

E Turk, Young Gasteiner, Senior Researcher, Institute of Health, Republic of Slovenia

SESSION III

Balanced and transparent decision making

The decision-making process should be unbiased, rigorous and transparent. It should seek to find the optimal balance between affordable health care and the use of innovative technologies.

K Chalkidou, Director, Policy Consulting, NICE, London, United Kingdom

Ausgewogene und transparente Entscheidungen

Der Entscheidungsprozess soll unvoreingenommen, strikt und transparent sein. Er sollte darauf ausgerichtet sein, die bestmögliche Balance zwischen bezahlbarer Gesundheitsversorgung und der Nutzung innovativer Technologien zu erreichen.

A Cicchetti, Director, Laboratory of Health Economics and Management, Catholic University of Rome, Italy

SESSION IV

Evidence required for best value outcomes

A wide range of evidence is needed to achieve optimal value for money. Although HTA will remain focused on cost-effectiveness and efficiency, it also has to cover organizational, social, legal and ethical aspects.

B Schwarz, Head of Karl Landsteiner Institute for Health Economics, Vienna, Austria

Notwendige Evidenz für bestmögliche Ergebnisse

Eine breite Evidenzbasis ist notwendig, um den bestmöglichen Wert für die aufgewendeten Mittel zu erreichen. Obwohl GTB weiterhin auf Kosten-effektivität und Effizienz fokussiert ist, müssen auch organisatorische, soziale, rechtliche und ethische Gesichtspunkte einbezogen werden.

R Taylor, Associate Professor in Health Service Research, Peninsula Technology Assessment Group, Royal Devon & Exeter Hospital, United Kingdom

Sponsored by an unrestricted educational grant from Merck Sharp & Dohme

Forum 3

Tackling health inequalities in Europe

Bewältigung von Ungleichheiten im Gesundheitsbereich in Europa

The size and scale of the differences in health of people living in different parts of the EU and between socially advantaged and disadvantaged citizens represents a challenge to the EU's commitment to solidarity and equality of opportunity. In an innovative approach Parallel Forums 3 and 4 will focus on the policy and research contexts of inequalities and social determinants of health with a view to illustrate how the inequalities agenda is being taken up by different Commission services.

Die Größe und das Ausmaß der Gesundheitsunterschiede der Bevölkerung in verschiedenen Teilen der EU und zwischen den sozial begünstigten und benachteiligten EU-Bürgern stellt eine Herausforderung für die Verpflichtung der EU zur Solidarität und Chancengleichheit dar. Anhand eines innovativen Ansatzes wird in den Parallel Forums 3 und 4 der Schwerpunkt auf Politik und Forschung zum Thema Ungleichheiten und sozialen Determinanten gelegt, um zu zeigen wie dieses Thema von verschiedenen Generaldirektionen der Kommission behandelt wird.

SESSION I	Against the backdrop of the financial crisis, this session will offer an opportunity to report on the European Commission 'Solidarity in Health' initiative on reducing health inequalities in the EU and response to the crisis.	
Meeting the challenge of health inequalities in the EU	Vor dem Hintergrund der Finanzkrise, wird die erste Session die Gelegenheit bieten, über die EC-Initiative und deren Reaktion auf die Krise zu berichten.	
Die Herausforderung der Gesundheitsungleichheiten in der EU	Introduction and outline Einleitung und Überblick	<i>R Madelin, Director General, DG SANCO, European Commission</i>
<i>Chair: R Madelin, Director General, DG SANCO, European Commission</i>	Tackling health inequalities in and between Member States Bewältigung von Ungleichheiten innerhalb und zwischen den Mitgliedsstaaten	<i>T Jiménez, Minister, Ministry for Health and Consumer Affairs, Spain (tbc)</i>
	What's needed to address health inequalities by gender and social group in Europe Wie können gender- und klassenbezogene Gesundheitsungleichheiten bewältigt werden?	<i>M Vassiliadou, Secretary General, European Women's Lobby</i>
	Ways out of the crisis – what can public health do? Wege aus der Krise – was kann Public Health beitragen?	<i>C Hörhan, Chief Executive, Fonds Gesundes Österreich, Austria</i>
	How can the use of structural funds reduce inequalities in Europe? Wie können Strukturfonds eingesetzt werden um Ungleichheiten in Europa zu reduzieren?	<i>J Walsh, Deputy Head of Unit, DG REGIO, European Commission (tbc)</i>
<i>Panel discussion</i> <i>Moderator: R Madelin</i>	What's needed to achieve success in European action to tackling health inequalities? Was wird benötigt, um Gesundheitsungleichheiten in Europa erfolgreich bewältigen zu können?	<i>J Leinen, MEP G Fischer, Head of Unit, DG EMPL, European Commission Speakers from above</i>

SESSION II	How can the EU Framework Programme for Research contribute to improve the knowledge base on the causes of health inequalities and the evidence base for action at EU level, giving shape to a European research agenda?	
Research on health inequalities in the EU – where are we, where do we want to go?	In welcher Form kann das EU-Forschungsrahmenprogramm einen Beitrag zur Verbesserung der Wissensbasis über die Ursachen von Ungleichheiten in der Gesundheit, sowie der Evidenzbasis für Maßnahmen auf europäischer Ebene, als europäische Forschungsagenda, leisten?	
Forschung über Gesundheitsungleichheiten in der EU – wer sind wir, wohin wollen wir?	Welcome Begrüßung	<i>K McCarthy, Head of Sector Public Health, DG RTD, European Commission</i>
<i>Chair: R Madelin, Director General, DG SANCO, European Commission</i>	Setting the scene and identifying the research agenda challenge Einführung und Bestimmung der Herausforderung für die Forschungsagenda	<i>Keynote speaker: M Marmot, Chairman, WHO Commission on Social Determinants</i>
	The landscape of EC funded research and public health projects Die Zusammensetzung EC finanzierter Forschungs- und Public Health Projekte	<i>U Karl-Trummer, Center for Health and Migration, Danube University Krems S Van den Broucke, Department of International Health, University of Maastricht</i>
	Contributing to policy development – EC funded research Beiträge zur Politikentwicklung – EK finanzierte Forschung	<i>C Knai, Young Gasteiner, Research Fellow, LSHTM, London</i>
	Contributing to policy development – EC Public Health Programme Beiträge zur Politikentwicklung – Public Health Programme der EK	<i>C Jagger, Department of Health Sciences, University of Leicester</i>



Hosted by the European Commission DG Health and Consumers & DG Research

Forum 4

Tackling health inequalities in Europe Bewältigung von Ungleichheiten im Gesundheitsbereich in Europa

Continuation from Forum 3

SESSION III

EC projects contributing to the health inequalities debate

EK-Projekte, die zur Debatte über Gesundheitsungleichheiten beitragen

Chair: C Segovia,
Deputy Director, Instituto de Salud Carlos III

Rapporteur:
S Van den Broucke,
Associate Professor,
Department of International Health,
University of Maastricht

An overview of EU-funded health research projects – both new and on-going – will be given together with actions supported by the EC public health programme, showing how EU research and actions generate evidence and add to the knowledge base for action and pinpointing gaps in knowledge and approaches.

Es wird ein Überblick über die EU-finanzierten Gesundheitsforschungsprojekte gegeben – sowohl für neue als auch laufende – zusammen mit den Maßnahmen, die vom EU-Programm für öffentliche Gesundheit unterstützt werden. Diese zeigen, wie EU-Forschung und Maßnahmen Evidenz generieren, sowie die Wissensbasis vergrößern und auf Wissenslücken und Ansätze, hinweisen.

EUROCADET

JW Coebergh, Erasmus Medical Center, University Medical Center, Rotterdam

IDEFICS

W Ahrens, Institute for Prevention Research and Social Medicine, University of Bremen

HOPE

F van Lenthe, Erasmus Medical Center, University Medical Center, Rotterdam (tbc)

DETERMINE & GRADIENT

C Costongs, Programme Manager, EuroHealthNet

HELENA

L Moreno, Professor, E.U. Ciencias de la Salud, Universidad de Zaragoza, Spain

EARNEST

B Koletzko, Professor, Dr von Hauner Children's Hospital, University of Munich

Panel Discussion: Setting the FP7 Health Research Agenda

Podiumsdiskussion: Festlegung der FP7 Gesundheitsforschungsagenda

Moderator: Clive Needle, Director, EuroHealthNet

F Adshead, Director, Chronic Disease and Health Promotion, WHO

D Vågerö, Member, WHO Commission on Social Determinants

E Szöllösi, Vice President, European Disability Forum Representative of the Young Gastein Forum

SESSIONS IV

Tackling health inequalities – Europe in action – Food, farming, physical activity and nutrition

Bewältigung von Gesundheitsungleichheiten – Europa in Aktion – Nahrungsmittel, Agrarwirtschaft, Bewegung und Ernährung

Chair: Clive Needle,
Director,
EuroHealthNet

Illustrating policy and research in action, the final session will show how concrete measures in a particular policy area, physical activity and nutrition, derive from different Commission services – DG Health and Consumers, DG Agriculture and DG Research – and link to WHO for the international perspective.

Zur Veranschaulichung wird gezeigt, wie sich in Politik und Forschung konkrete Maßnahmen aus bestimmten Politikbereichen von verschiedenen Kommissionsdienststellen – GD Gesundheit und Verbraucher, GD Landwirtschaft und GD Forschung – ableiten und wie sich die Verbindung zur internationalen WHO Perspektive darstellt.

DG Health and Consumers
GD Gesundheit und Verbraucher

E Robertson, SUHR'S University College, Copenhagen (tbc)

DG Research
GD Forschung

A Di Giulio, Head of Unit, DG RTD, European Commission
J Brug, Professor, University of Amsterdam, Netherlands

DG Agriculture
GD Landwirtschaft

Speaker tba

Discussion with the audience/Diskussion mit dem Publikum

Final conclusions
Schlussfolgerungen

Moderator: Clive Needle, Director, EuroHealthNet

S Van den Broucke, Department of International Health, University of Maastricht
Michael Hübel, Head of Unit, DG SANCO, European Commission
K McCarthy, Head of Sector Public Health, DG RTD, European Commission
Representatives of the Young Gastein Initiative



Hosted by the European Commission DG Health and Consumers & DG Research

Forum 5 Knowledge, transfer and action

This session will get to the heart of questions which underpin much of the work of the European Commission and other international institutions – how can we effectively learn from other countries and other sectors? How can we develop mechanisms and tools to help us learn more effectively and how do we identify what works for us in addressing a range of health issues? This session will include:

- What we know about how we learn from others and how we apply this, with examples from business, NGO, academic and health policy sectors
- How European innovation and policy can be translated into national action
- The tactics, tools and mechanisms to accelerate innovation into action and to help us to learn from each other
- Practical examples of how to learn from others

The sessions will include keynote presentations from experts in the field, panel discussion and in-depth work in interactive discussion clusters around the key issues.

Rapporteurs: S Feast, Senior Advisor, Health & Wellbeing, DH and I Wolfe, Honorary Research Fellow, LSHTM

SESSION I
Setting the scene

The first session will cover the theory of knowledge transferability, particularly in the European context. It aims to introduce the discussion on transferability of knowledge by looking at what we know and do not know about learning across countries.

Chair: N Boyd, International Health Policy Consultant, England

Transferring policy between countries: what transfers, what doesn't

H Wolman, Director, Institute of Public Policy, George Washington University, USA

Exploring the state of knowledge and how it is applied in differing sectors

Panel discussion with the audience

Comments on transferring policy between countries

L Fransen, Director, European Commission, DG Communication

SESSION II
How to transfer European innovation into national action

European health activities have increased tremendously. Yet there is very little knowledge if and to what extent they have had an impact on national or local health decision making. This knowledge is essential to improve the transformation process.

Chair: H Stein, Consultant, European Public Health Centre, Germany

Introduction: Need for impact assessments of European health policy

H Stein, Consultant, European Public Health Centre, Germany

The Influence of international strategies on systems for health

I Kickbusch, Senior Health Policy Advisor, Swiss Government

European engagement: differing country approaches

S Greer, Assistant Professor of Public Health, University of Michigan, USA

Europeanisation of national health policies – a dynamic but unsystematic process of policy adaption

W Lamping, Professor, University of Bremen, Centre for Social Policy Research, Germany

SESSION III
Mechanisms and processes to facilitate effective policy transfer

Looking at forms of transferring knowledge effectively to other countries, we will critically review and assess experience so far in terms of mechanisms and processes used to diffuse policy in the health field. How to make comparative analysis relevant, how to package information, how to share practice and experience usefully, how to target the right audience for policy transfer? These and other questions will be addressed.

Co-Chairs: J Figueras, Director, European Observatory on Health Systems and Policies, Belgium and M Davies, Principal Advisor, Department of Health England

Building health bridges or bridging diversity. What have we learnt?

J Figueras, Director, European Observatory on Health Systems and Policies

Panel discussion: Snapshots on transfer practice

*W Palm, Dissemination Development Officer, European Observatory on Health Systems and Policies
D McDaid, Senior Researcher, Health & Social Care, London School of Economics
K McCarthy, Head of Sector, Public Health, DG Research, European Commission
N Fahy, Head of Unit, Health Information, DG SANCO, European Commission*

SESSION IV
Health bridge

An interactive opportunity to learn from practical experience how information is actually transferred and received. How we can influence the shape and content of what is transferred, and the implications for how that is received. The Health Bridge simulation will create a realistic but imaginary country called Calma which is aspiring to join the EU. Participants will be grouped into small multi-national, multi-expert 'advisory groups' and be asked to work together to prepare their advice to Calma's President about what to do and how to do it. The participants then begin to think through their answer in the light of the experience of advising Calma, exploring what helps and hinders the effective transfer of learning across health systems.

Moderator & Chair: L McMahon, Professor of Health Policy, City University, London, UK

Sponsored by The International Collaboration on the Social Determinants of Health, The Department of Health, England

Forum 6

Shifting the paradigm – making healthcare sustainable

Shifting the paradigm – making healthcare sustainable

Healthy individuals enjoy a higher quality of life and lead to a healthy society, are more productive and contribute substantially to a sustainable long-term economic growth. A strong case can be made for investment in health. Prevention and the development of patient-centric integrated care is key to helping citizens enjoy healthier lives and boosting economic growth.

- Investing in and focusing care on disease prevention and disease management
- Encouraging patient-focused integrated treatment processes
- Speeding-up the adoption of innovative medical methods and technologies to enhance efficiency of healthcare
- Implementing value-based and outcome focused reimbursement systems

Rapporteur: C Erbe, Member of the Board, Deutsche Arbeiter Krankenkasse (statutory health insurance), Germany

SESSION I <i>Chair: KJ Schmitt, Vice-Chair, Sustainable Healthcare Focus Group, COCIR</i>	Healthcare sustainability – global and regional trends	<i>H Rosling, Professor for Public Health, Karolinska Institut, Stockholm (tbc)</i>
	Making Europe the healthiest region of the world	<i>J Chatzimarkakis, MEP, Alliance of Liberals and Democrats of Europe (ALDE)</i>
	The role of the Commission in the European healthcare system	<i>R Madelin, Director General, DG Health and Consumers, European Commission (tbc)</i>
	General conditions for doctors to work towards a healthier society	<i>M Wilks, President, Standing Committee of European Doctors (CPME)</i>
	The payer as a player in healthcare to increase transparency and competition	<i>J van Emelen, Director of Research & Innovation, Association Internationale de la Mutualité (AIM)</i>
	Increased quality and efficiency due to alternative care systems	<i>HD Nolting, Member of the Board, IGES Institute, Germany</i>

SESSION II <i>Chair: P Smit, Chair, Sustainable Healthcare Focus Group, COCIR</i>	The core cities health improvement collaborative – a new focus on prevention and intervention in England	<i>N Benge, Director of Health Improvement, NHS, Birmingham East and North, UK</i>
	Population based approach – EU guidelines for breast cancer screening	<i>L von Karsa, Director, Screening Quality Control Group, International Agency for Research on Cancer (IARC)</i>
	Telemedicine: evidence in a large scale centralized organisation	<i>A Darkins, Chief Consultant for Care Coordination, Veterans Health Administration USA (tbc)</i>
	Innovative telemedicine for chronic obstructive pulmonary diseases (COPD)	<i>J Sagasser, Director, Diagnostic Related Groups, Medical and Quality Management (tbc)</i>

Panel Discussion	<i>Moderator: M McKee, Professor of European Public Health, London School of Hygiene and Tropical Medicine</i> <i>H Rosling, Professor, Karolinska Institute, Stockholm</i> <i>J Chatzimarkakis, MEP, Alliance of Liberals and Democrats of Europe</i> <i>G Fischer, Head of Unit, DG Employment and Social Affairs, European Commission</i> <i>M Medgyaszai, Secretary of State for Health Policy, Hungary</i> <i>D van Deursen, Programme Manager, Health Care Innovation Platform, Dutch Ministry of Healthcare, Wellness and Sport</i> <i>M Wilks, President, Standing Committee of European Doctors (CPME)</i> <i>N Klusen, Chairman of the Board, Techniker Krankenkasse (statutory health insurance), Germany</i> <i>H von Wulfen, President, COCIR</i>
-------------------------	--

Sponsored by an unrestricted educational grant from COCIR, the European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry

Workshops

Workshop 1

Communicable diseases

Wednesday
30 September 2009
09:00–12:00



Fighting communicable diseases in times of crisis

Infectious diseases are moving targets and well-performing health systems are vital in their control and treatment. The current economic crisis is a critical new factor which may both increase the threat for new outbreaks as well as reduce the political attention and response capacity. Leadership is essential to protect populations and treat infected patients. This workshop will explore the preparedness and resilience of health systems to emerging infectious diseases, covering both the global agenda and international financing schemes. Specific examples will include swine influenza, multi-drug resistant TB, re-emerging HIV and, in particular, high risk groups where targeted programmes are needed.

Organised by The Global Fund to Fight AIDS, Tuberculosis and Malaria and the European Observatory on Health Systems and Policies

The challenge of communicable diseases for European health systems

M McKee, Research Director, European Observatory on Health Systems and Policies

Sustainable financing of communicable disease programmes and emerging infectious diseases

R Atun, Director, Strategy, Performance & Evaluation Cluster, The Global Fund

Preparedness for emerging infectious diseases

R Coker, Professor of Public Health, London School of Hygiene & Tropical Medicine

Panel discussion: fighting communicable diseases in Europe

WHO, ECDC, EU Commission, World Bank, Global Fund

Workshop 2

European health information

Wednesday
30 September 2009
09:00–12:00



European health information system and communication on diseases

Health information, knowledge sharing and current policy papers from the European Commission, DG Sanco, Health Information Unit will be presented. The workshop will be in two parts.

The first part will explain how the new European Union Health Information and Knowledge Sharing System will be set up and what it means to citizens, stakeholders, experts and politicians.

The second part will concentrate on the current European Union initiatives on chronic and rare diseases, focusing on rare diseases, cancer and Alzheimer's disease. All three communications will be presented and the workshop should give an opportunity for all participants to discuss the three topics.

Organised by the European Commission DG Health and Consumers

The Health Information and Knowledge Sharing System

N Fahy, Head of Unit, DG Sanco, European Commission

Comparable sources of data in the EU

H Buchow, Head of Section, European Statistical Office

Health indicators in the EU

P Kramers, External Expert, RIVM National Institute of Public Health and the Environment, Netherlands

Health reporting in the EU (for example EUGLOREH report, EUROPERISTAT report, ...)

E Göbel, Assistant Policy Officer, DG Sanco, European Commission

Council Recommendation and Commission Communication in the field of rare diseases

A Montserrat, DG Sanco, European Commission

Communication and Recommendation on Alzheimer and dementias

K McCarthy, Head of Sector Public Health, DG Research, European Commission

Communication on action against cancer

M Rupnik-Potokar, Policy Officer, DG Sanco, European Commission

Workshop 3

Swedish EU Presidency 2009

Wednesday
30 September 2009
18:30–20:00



Swedish EU Presidency 2009

Since 1 July 2008, Sweden has been working in a 'trio' with France and the Czech Republic to produce an 18-month work programme for the period 1 July 2008 to 31 December 2009. The Swedish government has also produced a specific six-month work programme for the Swedish Presidency.

The Ministry of Health and Social Affairs plays an active part in EU cooperation, including issues such as protection against infectious diseases, cross-border health care, pharmaceuticals, alcohol, narcotics and tobacco.

Exact topics of the workshop to be announced.

Organised by the Swedish Presidency – Ministry of Health and Social Affairs

Workshops

Workshop 4

Healthcare decision-making

Wednesday
30 September 2009
18:30–20:00

Healthcare decision-making: the challenge of balancing policy goals and stakeholders' interests

The EU and its member states face unprecedented pressures on public finances as a result of long-term demographic changes and short-term burdens imposed by the economic downturn. The value of efficient and rational decision-making has never been higher. The same is true of public awareness and expectations, creating a significant potential source of conflicts between what is expected and what is deliverable. Healthcare is in the eye of the storm and nowhere are the issues more challenging than in the management of technological change.

Healthcare systems are nowadays required not only to deliver healthcare but also to promote solidarity, equity and participation, be more responsive to people's needs and engage stakeholders (Tallin Charter) yet must operate in an overall framework of financial prudence and efficiency. Healthcare deciders are increasingly required to become experts in science, ethics, economics, data management, policy design and negotiation, yet they do not have a monopoly on the information needed for decision-making. The complexity (and potentially the effectiveness) of the decision-making process will be immeasurably deepened by the shift to personalised care, with its emphasis on personal choice and responsibility. Properly managed, better decision-making has a major contribution to make to the goals of the EU Health Strategy. What is the right balance between complexity, transparency and participation?



The workshop is sponsored by the European Federation of Pharmaceutical Industries and Associations

Workshop 5

Addressing antibiotic resistance

Friday
2 October 2009
16:00–19:00

Antibiotic resistance in Europe: the example of pneumococcal disease

Antibiotics are lifesavers, yet the adage 'prevention is better than cure' holds true, and measures, such as vaccination, offer proven cost-effective solutions.

Secondary protection, by inhibiting carriage of targeted antibiotic-resistant bacteria in the nose and throat, can be provided by certain vaccines. The synergy that occurs when such vaccines are combined with judicious use of antibiotics can be used by health authorities to deliver and maintain fundamental gains over antibiotic-resistant organisms. This workshop will look at antibiotic resistance in Europe using pneumococcal disease as a case study.

Introduction – Setting the scene: the EU agenda

J Clare, Managing Director, LionsDen Communications Ltd, United Kingdom

Antibiotic consumption in Europe: its impact on disease burden and disease management strategies

S Coenen, Post-Doctoral Fellow, Department of General Practice as of the Research Foundation-Flanders, University of Antwerp, Belgium

The burden of pneumococcal disease and the carriage of *S. pneumoniae*: a factor in antibiotic resistance, infection and transmission

H Nohynek, Professor of International Health, National Institute for Health and Welfare/University of Tampere, Finland

Vaccination against *S. pneumoniae* in the European Union

P Bonanni, Professor, Department of Public Health, University of Florence, Italy

Costs and benefits of vaccination against *S. pneumoniae* in national immunization programs in the European Union

P Beutels, Scientific Director, University of Antwerp, Centre for Health Economics Research & Modeling Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute, Belgium

Summary & conclusions

J Clare, Managing Director, LionsDen Communications Ltd, United Kingdom



The workshop is sponsored by Wyeth vaccines

Workshops

Workshop 6

Rare diseases

Friday
2 October 2009
16:00–19:00

How do we organise treatment of rare diseases in Europe: national activities and cross-border scientific and health policy perspectives

The management and treatment of patients suffering from rare diseases continues to be a high priority matter in all EU Member States. Moreover, the recommendations proposed by the EU Commission constitute an excellent basis for the development of national plans of action.

Meanwhile, all EU Member States have begun with the development of national plans of action, and some of them have already been completed. Even if the principles of the EU recommendations point the way forward, the national plans of action must be adapted to and be compatible with the respective national health system of the member state.

One must consider, however, that especially in connection with the diagnosis and treatment of rare diseases, networking between experts of EU Member States is of particular importance, more than in the case of many other health policy problems.

The workshop will be used to survey the current activities from different perspectives and to discuss issues concerning the initiation or consolidation of (cross-border) scientific and health policy networks in the area of rare diseases.

Moderator: M Moritz, former Head of ÖBIG, Austria (tbc)

Treatment of rare diseases: national and European implications from the patient's point of view
EURORDIS, France (tba)

Regional and national reference centers as guarantor for structural quality in the treatment of rare diseases
RB Galluppi, President, UNIAMO FIMR onlus, Federazione Italiana Malattie Rare, Italy

The Bulgarian National Plan for Rare Diseases - genetic disorders, congenital malformations and nonhereditary diseases (2009-2013)
R Stefanov, Country Coordinator, Orphanet Bulgaria, Department of Social Medicine and Health Management, Medical University of Plovdiv, Bulgaria

Development of an Austrian National Plan for Rare Diseases – comparison with other European countries
T Voigtländer, Country Coordinator Orphanet Austria, Institute of Neurology, Medical University of Vienna, Austria

Research on rare diseases: a European challenge
S Koutouzov, Secretary General, GIS-Institut des Maladies Rares, France

Panel discussion on the European perspective of rare disease treatment and the initiation or consolidation of trans-national scientific and health policy networks
EURORDIS, France (tba)
RB Galluppi, President, UNIAMO FIMR onlus, Federazione Italiana Malattie Rare, Italy
R Stefanov, Country Coordinator, Orphanet Bulgaria, Department of Social Medicine and Health Management, Medical University of Plovdiv, Bulgaria
T Voigtländer, Country Coordinator Orphanet Austria, Institute of Neurology, Medical University of Vienna, Austria
S Koutouzov, Secretary General, GIS-Institut des Maladies Rares, France
R Schlögel, Director General, Ministry of Health, Austria
W Sperl, Head of Department, Pediatrics and Adolescent Medicine, Paracelsus Medical University, Salzburg, Austria



Hosted by the Austrian Federal Ministry of Health

Workshop 7

Health professional mobility

Saturday
3 October 2009
09:00–13:00



European
Observatory
on Health Systems and Policies

Health professional mobility in Europe

Health professionals have always moved between countries in Europe. However, concerns about the scale of movements and their impacts have been increasing over recent years. With the financial and economic crisis these patterns are again undergoing rapid change, having severe impacts on health systems and posing challenges for both policy makers and stakeholders.

This workshop will explore what we know about the current changes and their consequences, and how policies at different levels (national, regional and EU) should address them.

Presenters, panellists, chairs and facilitators include:
M Wismar and W Palm, European Observatory on Health Systems and Policies
B Merkel, K Neubauer and W Dziworski, DG Sanco, European Commission
J Bremner, European Health Management Association
J Buchan, Queen Margaret University, Edinburgh, Scotland
M Szócska, Semmelweis University, Hungary
T Albrecht, Institute of Public Health, Republic of Slovenia
E van Ginneken, Research Fellow, Technical University, Berlin
G Perfilieva, WHO Regional Office for Europe (tbc)
G Ruscitti, Health and Social Services Veneto Region, Italy
S Williams, Royal College of Nursing, United Kingdom
AP Sanne, Directorate of Health, Norway (tbc)
FU Montgomery, Vice President, CPME

Hosted and organized by the European Observatory on Health Systems and Policies and the European Commission. It is supported by the European Health Management Association

Workshops

Lunch workshop 1

Medical technology

Thursday
1 October 2009
12:30–14:00

From economic challenge to opportunity for change: a strategic role for medical technology

It is increasingly being recognised that the current crisis can create opportunities for change. All players in the healthcare sector must work together to seek better ways for improving the process of healthcare delivery, with a view to maximising health production. Change resulting from the economic crisis can then lead to stronger, more efficient and more equitable healthcare systems.

The European Health Technology Institute for Socio-Economic Research (EHTI), a collaboration involving leading academic centres, policy-makers and industry, has invited eminent speakers to discuss and debate opportunities for change in healthcare systems and what role medical technology can play in facilitating such change.

Introduction

M Drummond, Professor, Centre for Health Economics, University of York, United Kingdom and EHTI

Health System Financing – a time for reform?

B Merkel, Head of Unit, DG Health and Consumers, European Commission

Can medical technology bring about change in health care delivery: what evidence do we have?

E Mossialos, Professor, London School of Economics & Political Science and EHTI

Changes in health care delivery – what role for medical technology?

Z Vercooteren, Executive Director, Government Affairs & Policy, Johnson & Johnson and EHTI

Discussion



Sponsored and organised by the European Health Technology Institute for Socio-Economic Research (EHTI)

Lunch workshop 2

Biopharmaceuticals benefits vs risk

Thursday
1 October 2009
12:30–14:00

Biopharmaceuticals: balancing benefits and risks –sharing responsibility

In recent years, thanks to biotechnology, the development of new medicines has made tremendous progress, and contributed to reducing the burden of diseases in Europe. The benefits and risks of novel therapies are the subject of societal debate, often focusing on the risks. However, what is often not fully reflected is the responsibility of each stakeholder group: researchers, industries, healthcare professionals, ethics committees, regulators and patients.

The workshop will examine the involvement of each stakeholder in the identification, assessment and management of risks during research and development, registration, marketing and prescription of a medicinal product. It will highlight the need for a balanced and shared responsibility where benefits are equally taken into consideration.

Introduction

E Chantelot, Executive Director, European Biopharmaceutical Enterprises

How much risk for how much benefit?

The patient's perspective

C Thalheim, Secretary General, European Multiple Sclerosis Platform

Shared responsibility for optimal patient outcomes

T Mundel, Global Head of Development, Novartis

When do benefits outweigh the risks?

The doctor's perspective

Speaker (tba)

Closing remarks



Sponsored and organised by EBE – European Biopharmaceutical Enterprises, Roche and Novartis

Lunch workshop 3

Cancer drug development

Thursday
1 October 2009
12:30–14:00

The impact of funding and policies on innovative cancer drug development

Cancer is the second largest killer in Europe. Incidence rates are increasing with more than two million new cases and more than 1.1 million cancer deaths in Europe each year. While the role of research and innovation is one of the fundamental elements in combating cancer, research funding and existing policies have a major impact on development of innovative cancer drugs.

This lunch workshop will address on the one hand, the role played by innovation in the fight against cancer, especially rare cancers in Europe and on the other hand, some of the key challenges and obstacles in the development of innovative cancer drugs.



Sponsored by Novartis Oncology

Workshops

Lunch workshop 4 Medical progress

Thursday
1 October 2009
12:30–14:00

Investing in medical progress: Discovering new indications for approved medicines

The pharmaceutical industry is often criticized for not being innovative enough. Investment in innovation, even in times of crisis, is a necessity to make a valuable contribution to long-term health needs.

This workshop will focus on one source of innovation which is often overlooked: important, new, additional indications of biotech medicines which are already on the market. Research into existing medicines has proven to yield benefits to patients and healthcare systems, as much as scientific breakthroughs on new medicines. However, bringing new indications to patients requires vast investments of time and resources in new R&D to guarantee quality and patient safety. It can take up to a decade for an indication to be developed and approved. How can such activities be economically protected to ensure they will continue to be undertaken by companies? What is the role of legislators? What is the risk of free-riding companies?

Expert speakers from authorities and the industry will look at how innovation is protected and how innovative new treatments can be ensured for the future.

Introduction

Driving innovation in the pharmaceutical industry towards improved patient outcomes

Identifying new indications for existing biological treatments – an introduction

Developing new indications – an innovation process

The economic argument for investing in new indications



Sponsored by AMGEN

Dinner workshop 1 Cancer: a unified approach

Thursday
1 October 2009
18:00–20:30

The unified approach: meeting the cancer challenges in the next decade

This session focuses upon ECCO's latest initiatives to structure the oncology community's response and thus strengthen European policy on cancer. Only through such a unified approach can the European oncology community best engage with all stakeholders and become a major player in the development of European cancer health and research policy to promote the interest of cancer patients, those who care for them, and those without whose research there would be no advances in treatment and care.

Session highlights include:

Introduction to the newly-created European Academy of Cancer Sciences

Ideas on the creation of a world-class European Platform for Translational Cancer Research

Exchange of views on the 'European Partnership Against Cancer'



Hosted by ECCO – The European Cancer Organisation

Dinner workshop 2 Hospitals of the future

Thursday
1 October 2009
18:00–20:30

Investing in hospitals of the future

Investing in hospitals requires, particularly in a context of economic recession, strategic reflection on the future role of a hospital in the wider context of its health system. Hospital planning, financing and design need to allow flexibility to address changing roles and circumstances. Decisions about hospital configuration and construction should aim to optimise performance and maximize health gains.

What is the impact of systematised models of care on hospital function? How should hospitals be structured conceptually and as actual buildings? Which financing mechanisms are most appropriate? How can the life-cycle of health facilities be taken into account at the design stage? How can hospitals be made more environmentally sustainable and adaptable?

Overview, and interface with new healthcare service models: conceptualising hospitals for the future
S Wright, Executive Director, European Centre for Health Assets and Architecture (ECHAA)

Capital investment in hospitals: strategic planning and decision-making in an uncertain environment
B Dowdeswell, Director of Research, European Centre for Health Assets and Architecture (ECHAA)

The evidence base: case studies of recent hospitals and system reform
B Rechel, Researcher, European Observatory on Health Systems and Policies

Panel discussion: planning, financing and managing the hospital of the future.
Facilitator: M McKee, Research Director, European Observatory on Health Systems and Policies



Organised by the European Centre for Health Assets and Architecture and the European Observatory on Health Systems and Policies

About the conference

The EHFG is the leading health policy conference in Europe. The main objective is to facilitate the establishment of a framework for advising and developing European health policy while recognising the principle of subsidiarity.

Das EHFG ist die führende gesundheitspolitische Konferenz Europas. Das Hauptziel ist die Herstellung eines Rahmens zur Beratung und Entwicklung einer europäischen Gesundheitspolitik unter Berücksichtigung des Subsidiaritätsprinzips.

Target group

Those participating in the event include senior policy and decision-makers representing politics and government at EU, national and regional levels; business and industry; health care funders and service providers; civil society; as well as experts and researchers in health care and public health.

Zielgruppe

Bei den Teilnehmern handelt es sich um Entscheidungsträger aus den Bereichen, Politik und Verwaltung auf EU, nationaler und regionaler Ebene, Wirtschafts- und Industrievertreter, Versicherungen und Dienstleistungsanbieter, Zivilgesellschaft sowie Experten und Forscher aus den Bereichen Gesundheitsversorgung und öffentliche Gesundheit.



Besides the official programme, the event provides a vast array of opportunities for informal meetings, discussion and networking

Neben dem offiziellen Programm, bietet die Veranstaltung eine Vielzahl von Möglichkeiten für informelle Treffen, Diskussion und Networking



Bad Hofgastein

The Gastein valley lies at the heart of the 'Hohe Tauern' nature reserve, the largest of its kind in Central Europe. World famous for its thermal springs it is a year round tourist resort offering a large range of high-quality accommodation. Most congress hotels are within walking distance of the congress venue which is located in the centre of this typical Austrian village.

Das Gasteinertal liegt im Herzen des Nationalparks "Hohe Tauern", dem größten seiner Art in Zentraleuropa. Weltbekannt für seine heißen Thermalquellen ist es eine ganzjährige Tourismusdestination, die eine Auswahl an Unterkünften von hoher Qualität bietet. Die meisten Kongresshotels können vom Veranstaltungsort, der sich im Zentrum dieser typischen österreichischen Ortschaft befindet, zu Fuß erreicht werden.

Young Forum Gastein Initiative

The Young Forum Gastein initiative is a joint project of the European Health Forum Gastein and the European Commission (DG Health and DG Research) aimed at young researchers and officials from Member States of the European Union working in the field of health. The purpose of the initiative is to introduce promising young decision-makers and experts to the Gastein process – bridging the gap between research and policy-making and facilitating learning and networking across Europe.

The Young Gastein Initiative was launched on the occasion of the 10th anniversary of the EHFG and is now entering its third year. Following the great success of the previous years and the encouraging feedback the European Health Forum Gastein intends to continue the initiative and to build a sustainable network.



Die Young Forum Gastein Initiative ist ein Gemeinschaftsprojekt des European Health Forum Gastein und der Europäischen Kommission (GD Gesundheit und GD Forschung), es richtet sich an junge Forscher und Entscheidungsträger aus den Mitgliedsstaaten der Europäischen Union, die im Gesundheitsbereich tätig sind. Das Ziel hinter dieser Initiative ist es junge Entscheidungsträger und Experten den Gastein-Prozess näher zu bringen, sowie die Kluft zwischen Forschung und Politik zu überbrücken, das Lernen voneinander, sowie die Bildung eines Netzwerkes zu unterstützen.

Die Initiative wurde im Rahmen des 10jährigen Bestehens des EHFG ins Leben gerufen und findet dieses Jahr zum dritten Mal statt. Aufgrund des guten Gelingens der vorhergehenden Jahre, sowie der positiven Rückmeldungen beabsichtigt das EHFG dieses Projekt weiterzuführen und ein nachhaltiges Netzwerk aufzubauen.



Neuschwanstein

Come to see one of the most popular castles in Europe: Neuschwanstein was built by the Bavarian King Ludwig II between 1869 und 1886. Seven weeks after his death it was opened for the public. The king who was afraid of the public built this castle as his refuge. Nowadays his hideaway became a crowd puller. Built and equipped in medieval style, but with modern technology at that time period. The castle Neuschwanstein is the most famous building of historism and the epitome of the German idealism.

Neuschwanstein

Besuchen Sie mit uns eines der meistbesuchten Schlösser Europas: Neuschwanstein wurde vom Bayernkönig Ludwig II in der Zeit von 1869 bis 1886 errichtet. Sieben Wochen nach dessen Tod wurde es dem Publikum geöffnet. Der menschenscheue König hatte die Burg erbaut, um sich aus der Öffentlichkeit zurückzuziehen – jetzt wurde sein Refugium zum Publikumsmagneten. Erbaut und ausgestattet im mittelalterlichen Stil, aber mit damals modernster Technik, ist Schloss Neuschwanstein das berühmteste Bauwerk des Historismus und der Inbegriff des deutschen Idealismus.

Dolomites Round Trip

As a powerful peak the Dolomite Alps elevate like a lime rock island amongst a dark sea of granite and gneiss in the regions of Trentino-South Tyrol and Belluno. “The most beautiful mountains of the world”, “the queen of the Alps”: Two names, that make clear, that a drive through the Dolomites offers a unique adventure. Those who once climbed the massive of the Langkofel, enjoyed the great view at the Sellajoch or admired the bizarre world of the Dolomites on top of the Col Raiser, will definitely agree.

Dolomiten-Rundfahrt

Als mächtige Felsgipfel erheben sich die Dolomiten wie eine Kalksteininsel inmitten eines dunklen Meeres aus Granit und Gneis in den Regionen Trentino-Südtirol und Belluno. „Das schönste Gebirge der Welt“, „die Königin der Alpen“: Zwei Bezeichnungen, die deutlich machen, dass eine Fahrt durch die Dolomiten ein Erlebnis der Extraklasse bietet. Wer einmal das monumentale Felsmassiv des Langkofels umwandert, die herrliche Aussicht auf dem Sellajoch genossen oder auf dem Col Raiser die bizarre Dolomitenwelt bewundert hat, der kann diesen Auszeichnungen nur zustimmen.



Salzburg and its historic district – a unique treasure

The city of Salzburg, in particular, its historic district represents one of the most beautiful spots on earth. This has been internationally recognized through the inauguration as UNESCO World Cultural Heritage in 1997. Explore the beauty of Salzburg with a guided tour through historic roads and enchanted alleys.

Salzburg und seine Altstadt – ein einzigartiger Schatz

Tatsächlich stellt die Stadt Salzburg – und hier besonders ihre historische Altstadt – einen der schönsten Plätze der Erde dar, den man in Europa finden kann, was ja auch durch die Ernennung zum Weltkulturerbe durch die UNESCO im Jahre 1997 internationale Anerkennung fand. Entdecken Sie Salzburgs Schönheit bei einem geführten Bummel durch die Strassen und Gassen.

Alpentherme Gastein – the easy way to well-being

Leave daily life behind and just drift away – nothing easier than that in the six adventure and wellness worlds of the Alpentherme Gastein. Your individual wellness needs are met to perfection. Whether you are looking for fun, calmness or physical activity – you're bound to discover worlds of opportunities.

Alpentherme Gastein – Wohlfühlen leicht gemacht

Den Alltag draußen lassen und sich entspannt treiben lassen – nirgends ist das einfacher als in einer der sechs Erlebnis- und Wohlfühlwelten der Alpentherme Gastein. Individuelle Wellness-Wünsche werden perfekt erfüllt. Egal ob Sie Spaß, Ruhe oder Bewegung suchen – Sie werden unendliche Möglichkeiten entdecken!



Additional trips will allow you to explore the surroundings of Bad Hofgastein: the Großglockner – Austria's highest mountain, the unique Mountain Health Gallery, a walking tour through Bad Hofgastein and to the 'Krimmler' Waterfalls. You will also be able to enjoy a morning hike as well as golfing and archery.

Im Rahmen zusätzlicher Ausflüge werden Sie die Gelegenheit haben, die Umgebung von Bad Hofgastein zu erkunden: Österreichs höchsten Berg, den Großglockner, den einzigartigen Gasteiner Heilstollen, eine Führung zu Fuß durch Bad Hofgastein und zu den Krimmler Wasserfällen. Entspannen und Relaxen bei einer Almwanderung in der Früh, sowie beim Golfen oder Jagdbogenschießen.

Organiser:
International Forum Gastein

Coorganisers:
Federal Ministry of Health
Austrian Broadcasting Corporation



Supported by and in collaboration with:
European Commission, DG Health and Consumers
European Commission, DG Research
European Observatory on Health Systems and Policies
World Health Organization, Regional Office for Europe
Land Salzburg
World Bank

Supporting Organisations:
Baxter
European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry (COCIR)
Department of Health for England
Europabio
FIPRA International
GlaxoSmithKline
Hilfswerk Austria
Hoffmann La Roche
Merck, Sharpe & Dohme
Ministry of Health and Social Affairs, Sweden
Ministry of Health, Taiwan
Österreichische Ärztekammer
Paracelsus Medical University

Booking Information

We provide a variety of services to assist you during your stay. Booking the congress and your accommodation through the International Forum Gastein will ensure that you benefit from the following services: direct shuttle service from Salzburg Airport (60 minutes) or Schwarzach-St. Veit/Bad Hofgastein railway stations; participation in EHFG sessions (restrictions may apply) and social events for all participants and partners including the weekend, if you choose to stay until Saturday or Sunday.

For further information and a registration form please contact the booking hotline or visit our homepage at www.ehfg.org. Hotel rates are available upon request. Accompanying persons (non-participants) staying in the same room pay 60% of the regular hotel rates.

All information in this announcement is subject to change

Buchungsinformationen

Wir bemühen uns, Ihren Besuch so angenehm wie möglich zu gestalten. Wenn Sie den Kongress und Ihr Hotel über das Internationale Forum Gastein buchen, stellen Sie sicher, dass folgende Leistungen inbegriffen sind: Direkter Transferdienst vom Flughafen Salzburg (60 Minuten) oder den Bahnhöfen Schwarzach-St. Veit/Bad Hofgastein; Teilnahme an EHFG Veranstaltungen (Einschränkungen sind möglich); gesellschaftliche Rahmenveranstaltungen für alle Teilnehmer und Begleitpersonen einschließlich des Wochenendes, wenn Sie sich entscheiden bis Samstag oder Sonntag zu bleiben.

Für Einzelheiten und ein Anmeldeformular kontaktieren Sie bitte die Buchungshotline oder besuchen Sie unsere Homepage unter der Internetadresse www.ehfg.org. Hotelpreise sind auf Anfrage erhältlich. Nicht am Kongress teilnehmende Begleitpersonen im gleichen Zimmer zahlen 60% des regulären Hotelpreises.

Änderungen der Informationen dieser Programmankündigung bleiben vorbehalten.

CONGRESS FEES includes 20% VAT
KONGRESSGEBÜHREN inklusive 20% MwSt

Standard fee
Standardgebühr

EUR 1,700

Reduced fee: a contribution towards costs, available only to representatives of consumer/patient organisations and full-time staff of universities
Reduzierte Gebühr: Ein Kostenbeitrag, nur anwendbar auf Vertreter von Konsumenten/Patientenorganisationen und Vollzeitpersonal von Universitäten

EUR 465

Cancellation fee is 10% of the total amount due until 4 September 2009, 50% thereafter. Cancellation must be submitted in writing.

Die Stornogebühr beträgt bis 4. September 2009 10% des Gesamtbetrages, danach 50%. Stornierungen gelten nur schriftlich.

